ProPhase Labs shares fall 13.51% after hours as Q3 earnings concerns and proxy vote urgency weigh on liquidity.

ProPhase Labs (PRPH) fell 13.5% in after-hours trading following a Q3 earnings call that highlighted challenges in monetizing its BE-Smart™ esophageal cancer diagnostic despite a key U.S. patent. The company’s urgent call for shareholders to vote on proxy proposals by November 23 has heightened governance uncertainty, while liquidity constraints—$169K in cash and a $1.1M working capital deficit—intensified investor concerns. Technical indicators, including an oversold RSI and bearish MACD divergence, further fueled the selloff. A planned investor webinar on December 1 and ongoing efforts to recover $50M in accounts receivable through Crown Medical Collections underscore the market’s skepticism about management’s execution capabilities. The decline contrasts with a mixed healthcare sector and reflects broader doubts over commercialization prospects amid regulatory and financial hurdles.